MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example CarePlan: MTB-Beschluss Kim Musterperson

English

Profile: MII PR MTB Therapieplan version: 2027.0.0-ballot.1

status: Active

intent: Plan

category: prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie)

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-28

addresses: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

supportingInfo: ClinicalImpression: status = completed; effective[x] = 2023-01-20 --> 2023-03-28

activity

outcomeReference: Procedure Chemotherapy

reference: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: ServiceRequest Referral to clinical trial (procedure)

activity

reference: MedicationRequest: extension = 3,Predictive value of the biomarker or clinical effectiveness of the drug in a molecularly stratified cohort was demonstrated in a retrospective cohort or case–control study in the same tumor type.,http://www.ncbi.nlm.nih.gov/pubmed#35665782,http://www.ncbi.nlm.nih.gov/pubmed#37870536,http://doi.org#10.1200/JCO.2023.41.17_suppl.LBA3000; status = draft; intent = proposal; medication[x] = Trastuzumab deruxtecan; authoredOn = 2023-03-28

activity

reference: RequestGroup Chemotherapie + zielgerichtete Substanzen

activity

reference: RequestGroup zielgerichtete Substanzen

activity

reference: MedicationRequest: extension = 6,Preclinical data (in vitro, in vivo models or functional genomics studies) demonstrate that the biomarker predicts response to a specific drug treatment, supported by scientific rationale.,http://www.ncbi.nlm.nih.gov/pubmed#31209687; status = draft; intent = option; medication[x] = COBIMETINIB; authoredOn = 2023-03-28

activity

reference: ServiceRequest Genetic consultation (procedure)

activity

reference: ServiceRequest Refer for histology (procedure)

activity

reference: ServiceRequest Biopsy (procedure)